The SCOR application process is now open.
The SCOR program intends to bring together distinguished investigators from one or several institutions to develop a focused research Center, foster new interactions and cooperation, and enhance interdisciplinary research among the participants to understand the causes of various hematological malignancies and ultimately develop effective treatments for cancer patients.
Research areas may include, but are not limited to, the following:
- Mechanisms underlying the development of hematological malignancies. Our understanding of the molecular basis of cancer is leading to the development of predictive tests and targeted therapeutics. The LLS recognizes that understanding the basic mechanisms of hematological diseases, using state of the art technologies, forms the foundation of new therapies.
- Biomarkers (including biomarkers for early detection, diagnosis, prognosis, risk stratification, treatment management). The development of validated biomarkers and pharmacodynamic endpoints will be valuable in guiding the future of medicine for hematological diseases. Many hematological malignancies offer the opportunity to monitor the disease state at a molecular level. Application of these methods for disease management will be very useful in the future.
- Therapies (including small molecules, biologics, gene- and DNA/RNA-based therapies, cell therapies, and immunotherapies). The LLS is very interested in supporting well-justified therapeutic approaches to all types of blood cancers. The aim of these efforts should be to significantly extend the lives of patients, or, for certain blood disorders, provide curative intent, with an excellent safety profile. We encourage applications that apply the principals of precision medicine and use sophisticated animal models to predict responsiveness to molecular therapies. In addition, with the advances in our understanding of the immune system and immunotherapies, the LLS encourages the submission of applications that focus on harnessing the immune system for therapeutic intent.
- Stem cell transplantation (including but not limited to allogeneic, autologous, non-myeloablative). As HSCT provides effective therapy for some patients with blood cancer, improving upon current methods is valuable.
Not to exceed $1.0 million per year, which includes direct and indirect costs. Aggregate costs over five years cannot exceed $5.0 million. Direct costs, if justified by the aggregate budget, may be up to $0.833 million per year. The indirect or institutional costs cannot exceed 20 percent of the direct costs per year.
To be funded in this program, the proposed research must be multidisciplinary and the Center must demonstrate synergy among at least three research projects; these may be supported by scientific Core laboratories. LLS permits an application for continued funding beyond five years for current SCORs. These applications compete with all proposals submitted in that application year.
How to Apply/Deadlines
LLS uses its own Research Portal powered by FLUXX for Letter of Intent (LOI) and full application submission.
All times are Eastern Time (ET)
|Call for Proposals:||September 2015|
|Letter of Intent Deadline:||November 2, 2015||3:00 PM ET|
|Notice of Full Application Invitation:||December 30, 2015|
|Full Application Deadline:||March 16, 2016||3:00 PM ET|
|Scientific Peer Review Committee:||May 2016|
|Notification of Awards:||June 30, 2016|
|Funding Start Date:||October 1, 2016|